Related Experiment Videos
Angiogenesis (clinical trials)
1Angiogenesis Research Center and BIDMC/Harvard Medical School, Boston, MA 02215, USA. rlaham@bidmc.havard.edu
Abstract:
Therapeutic angiogenesis may play a role in the treatment of patients with vascular disease who have no other treatment option (those who are not candidates for bypass surgery or angioplasty). The first published clinical trial results appeared in 1998 and additional trials have since been completed or are ongoing. Results of several of these trials are reviewed. Studies of angiogenesis with basic fibroblast growth factor and human vascular endothelial growth factor suggest that these growth factors can induce functionally significant angiogenesis. Evolving delivery modalities and strategies are also highlighted.
Insights
Therapeutic angiogenesis shows promise for treating vascular disease in patients ineligible for surgery. Growth factors like FGF and VEGF can stimulate new blood vessel growth, offering new treatment strategies.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Biotechnology
Background:
- Vascular disease impacts patients lacking surgical options.
- Therapeutic angiogenesis presents a potential alternative treatment.
- Early clinical trials began in 1998.
Purpose of the Study:
- To review clinical trial results for therapeutic angiogenesis.
- To assess the efficacy of growth factors in inducing angiogenesis.
- To highlight advancements in delivery methods for angiogenesis therapies.
Main Methods:
- Review of published clinical trial data on therapeutic angiogenesis.
- Analysis of studies using basic fibroblast growth factor (FGF) and human vascular endothelial growth factor (VEGF).
- Evaluation of evolving delivery modalities and strategies.
Main Results:
- Growth factors like FGF and VEGF demonstrate the ability to induce functionally significant angiogenesis.
- Several clinical trials have been completed or are ongoing, with results under review.
- Advancements in delivery systems are enhancing therapeutic potential.
Conclusions:
- Therapeutic angiogenesis is a viable option for specific vascular disease patients.
- Growth factor-induced angiogenesis is effective in promoting new blood vessel formation.
- Ongoing research and evolving delivery strategies continue to advance this field.